Year: 2024

ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITPPivotal phase 3 data show rapid and durable platelet response, reduced bleeding and need for rescue response, and improved physical fatigue and quality of life measures in patients with persistent or chronic ITP Results underscore the safety and efficacy of rilzabrutinib and its potential as the first BTK inhibitor in ITP Rilzabrutinib is currently under regulatory review in the US and the EUParis, December 7, 2024. Positive results from the pivotal LUNA 3 phase 3 study of rilzabrutinib in adults with persistent or chronic immune thrombocytopenia (ITP), a rare immune-mediated disease, reinforce the efficacy and safety of rilzabrutinib, an oral, reversible, covalent Bruton’s tyrosine kinase (BTK) inhibitor, and further...

All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to 60%, a decrease in hemoglobin S to

Hamilton, Bermuda. December 7, 2024. Avance Gas Holding Ltd. («Avance Gas» or «Company») (OSE: AGAS) refers to the announcement on August 15, 2024, regarding the sale of its VLGC fleet to BW LPG Ltd (“BW LPG” or “Buyer”) for $1,050 million. Today Avance Gas announces the seventh VLGC delivery, the 2015-built vessel Pampero. In connection with the delivery, 1.350 million shares in BW LPG were issued by the Buyer to Avance Gas. The ship mortgage has been repaid and Avance Gas expects to receive net cash proceeds of approximately $7 million. Following the delivery, Avance Gas owns 10.991 million shares in BW LPG corresponding to a 7.28% ownership share. These consideration shares have a lock-up period of 40 days from the issuance date as previously announced. Pampero is currently on a variable Time Charter expiring...

Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; initial clinical data planned for 2025 – Conference Call on Saturday, December 7th at 9:00 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 07, 2024 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data as of a July 5, 2024 data cutoff from the ongoing phase 1/2 trial of petosemtamab, a Biclonics® targeting EGFR and LGR5, in previously treated (2L+) patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC)....

VANCOUVER, British Columbia, Dec. 06, 2024 (GLOBE NEWSWIRE) — Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the “Company” or “Fobi”), is an industry leader in harnessing AI and data intelligence to enable digital transformation. As a result of a review by the British Columbia Securities Commission, Fobi is issuing the following press release to clarify our disclosure on the information previously included in the Company’s management information circulars (“Circular”) concerning CEO Rob Anson’s total percentage of ownership regarding direct and indirect holdings in the Company (“Shareholdings”).  The Shareholdings are calculated based on the issued and outstanding of the Company at the record date reported in each respective Circular.Total % of Issued and Outstanding    Reported in Circular Actual...

VANCOUVER, British Columbia, Dec. 06, 2024 (GLOBE NEWSWIRE) — Fobi AI Inc. (FOBI:TSXV) (FOBIF: OTCQB) (the “Company” or “Fobi”), an industry leader in harnessing AI and data intelligence to enable digital transformation, is committed to maintaining transparency and continuous communication with its stakeholders regarding the recent cease trade order (“CTO”) issued by the British Columbia Securities Commission. The Company, in collaboration with its auditors, is actively working to finalize the audit and filing of its financial statements for the fiscal year ended June 30, 2024, as well as the related management discussion and analysis (“2024 Annual Filings”). These filings were due on October 28, 2024, and the Company is dedicated to ensuring compliance with all applicable standards and regulatory requirements (“Standards”). Fobi...

VANCOUVER, British Columbia, Dec. 06, 2024 (GLOBE NEWSWIRE) — Rugby Resources Ltd. (“Rugby” or the “Company”) (TSX-V: RUG) is pleased to provide the voting results from its Annual General & Special Meeting (“AGSM”) that was held on December 5th in Vancouver, British Columbia. A total of 80,582,317 common shares of the Company were voted, representing 25.45% of the Company’s outstanding shares. Shareholders voted in favour of all applicable items of business set before the meeting, as follows:  Percentage of Votes CastNumber of Directors % For % AgainstNumber of Directors to be set at five (5) 99.98% 0.02%Election of Directors % For % of Votes WithheldBryce Roxburgh 94.62% 5.38%Yale R. Simpson 94.62% 5.38%Robert Reynolds 99.98% 0.02%Cecil Bond 94.62% 5.38%Paul Joyce 94.62% 5.38%Appointment of Auditor %...

VANCOUVER, British Columbia, Dec. 06, 2024 (GLOBE NEWSWIRE) — Mustang Energy Corp. (CSE:MEC, OTC:MECPF, FRA:92T) (“Mustang” or the “Company”) is excited to announce that it has completed the first milestone (the “First Milestone”) of the previously announced option agreement (the “Agreement”) with Skyharbour Resources Ltd. (TSX-V: SYH) (“Skyharbour”) dated November 12, 2024. Pursuant to the Agreement, Skyharbour agreed to grant the Company an option to acquire an undivided 75% interest (the “Option”) in Skyharbour’s 914W Uranium Project (the “914W Project”), located in the Athabasca Basin of Northern Saskatchewan. For more information regarding the Agreement, please refer to the Company’s news release dated November 13, 2024. The Company completed the First Milestone on November 27, 2024 (the “Closing Date”) by making a cash payment...